Show Summary Details
Page of

Acute leukaemias 

Acute leukaemias
Chapter:
Acute leukaemias
Author(s):

Adele K. Fielding

, Charles G. Mullighan

, Dieter Hoelzer

, Eytan M. Stein

, Ghada Zakout

, Martin S. Tallman

, Yishai Ofran

, Jacob M. Rowe

, and Ross L. Levine

DOI:
10.1093/med/9780199656103.003.0051
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 August 2019

This chapter covers acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), and includes information on prognostic factors, current standard of care, basic biology, epidemiology, clinical presentation, diagnosis, pathophysiology, aetiology, and management. Although the majority of patients with acute myeloid leukaemia (AML) achieve complete remission with induction chemotherapy, relapse after achievement of clinical remission remains the most critical clinical challenge facing AML patients and clinicians today, with a pressing need to improve prognostication. Prognostic factors in acute lymphoblastic leukaemia is to stratify patients into good- and poor-risk groups and to adapt different treatment strategies accordingly. There are principally two phases to evaluating prognostic factors; the first is the patient characteristics at diagnosis and the second is the response to treatment.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.